Corbus Pharmaceuticals(US:CRBP)2026-03-09 11:43Financial Performance - Corbus Pharmaceuticals reported a net loss of approximately $20.6 million for Q4 2025, compared to a net loss of $9.5 million in Q4 2024, representing a 117% increase in losses year-over-year [12]. - The company reported a net loss per share of $1.25 for Q4 2025, compared to $0.78 for Q4 2024 [12]. - Total stockholders' equity increased to $147.5 million as of December 31, 2025, up from $142.4 million in 2024 [24]. Operating Expenses - Operating expenses increased by $9.4 million to approximately $22.0 million in Q4 2025, primarily due to higher clinical development expenses [13]. Funding and Cash Position - The company completed a public offering in Q4 2025, raising $75 million in gross proceeds, extending its cash runway into 2028 [6][14]. - The company had $163.3 million in cash, cash equivalents, and investments on hand as of December 31, 2025, expected to fund operations into 2028 [14]. Clinical Development - CRB-701 demonstrated an unconfirmed objective response rate of 47.6% in HNSCC, 37.5% in cervical cancer, and 55.6% in bladder cancer at the 3.6 mg/kg dose [7]. - CRB-913 showed a potent and rapid weight loss of 2.9% at 14 days in a dedicated obesity cohort, with favorable gastrointestinal safety [6][10]. - CRB-913's 12-week obesity study (n=240) is on schedule for completion in summer 2026 [6]. - Corbus anticipates key data readouts for CRB-701 and CRB-913 in mid-2026, focusing on efficacy, safety profiles, and clinical utility [4][10].